ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SIBP-A18

Its studies are led by Sinopharm.

Furthest: phase 1, since May 14, 20251 company-led study, 1 open or runningNext primary completion: May 15, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinopharm11 open or runningphase 1since May 14, 2025May 14, 2025May 15, 2028phase 1 · NCT06985368

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2025First study: phase 1 study in Solid Tumor MalignancyFirst studyNCT06985368 · 156 planned · China

Ahead

  1. May 15, 2028Primary completion: phase 1 study in Solid Tumor MalignancyNCT06985368

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06985368Solid Tumor Malignancy · China1RecruitingMay 15, 2028156

How it is read

Names in the registry

  • “SIBP-A18”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.